ACUTE AND SUBACUTE GASTROINTESTINAL AND GENITOURINARY TOXICITY PROFILES OF METFORMIN VERSUS PLACEBO PLUS PROSTATE AND PELVIC RADIOTHERAPY FOR THE MANAGEMENT OF HIGH RISK PROSTATE CANCER: INTERIM TOXICITY RESULTS OF A DOUBLE-BLINDED, MULTICENTRE, PHASE II RANDOMIZED CONTROLLED TRIAL

被引：0
|
作者：
McDonald, Megan O. [1 ]
Usmani, Nawaid [2 ]
Ong, Aldrich [1 ]
Koul, Rashmi [1 ]
Dubey, Arbind [1 ]
Ahmed, Shahida [1 ]
Quon, Harvey [3 ]
Yee, Don [2 ]
Parliament, Matthew [2 ]
Sivananthan, Gokulan [1 ]
Danielson, Brita [2 ]
Rowe, Lindsay [2 ]
Rose, James [4 ]
Hunter, William [1 ]
Sanghera, Karan Paul [2 ]
Ghosh, Sunita [2 ]
Kim, Julian O. [1 ]
机构：
[1] Univ Manitoba, Winnipeg, MB, Canada
[2] Univ Alberta, Edmonton, AB, Canada
[3] Univ Calgary, Calgary, AB, Canada
[4] Univ British Columbia, Vancouver, BC, Canada
来源：
RADIOTHERAPY AND ONCOLOGY | 2020年 / 150卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2
引用
收藏
页码：S4 / S5
页数：2
相关论文
共 28 条
  • [1] Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial
    Kim, Julian O.
    McDonald, Megan O.
    Ong, Aldrich
    Koul, Rashmi
    Dubey, Arbind
    Hunter, William
    Ahmed, Shahida
    Quon, Harvey
    Yee, Don
    Parliament, Matthew
    Sivananthan, Gokulan
    Danielson, Brita
    Rowe, Lindsay
    Ghosh, Sunita
    Usmani, Nawaid
    RADIATION ONCOLOGY, 2021, 16 (01)
  • [2] Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial
    Julian O. Kim
    Megan O. McDonald
    Aldrich Ong
    Rashmi Koul
    Arbind Dubey
    William Hunter
    Shahida Ahmed
    Harvey Quon
    Don Yee
    Matthew Parliament
    Gokulan Sivananthan
    Brita Danielson
    Lindsay Rowe
    Sunita Ghosh
    Nawaid Usmani
    Radiation Oncology, 16
  • [3] Preliminary results of RTOG 0831, a randomized, double-blinded, placebo-controlled trial of tadalafil in the prevention of erectile dysfunction in patients treated with radiotherapy for prostate cancer
    Bruner, Deborah
    Pugh, Stephanie L.
    Pisansky, Thomas Michael
    Greenberg, Richard Evan
    Pervez, Nadeem
    Reed, Daniel R.
    Rosenthal, Seth A.
    Mowat, Rex B.
    Raben, Adam
    Buyyounouski, Mark K.
    Kachnic, Lisa A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).
    Koontz, Bridget F.
    Karrison, Theodore
    Pisansky, Thomas Michael
    Posadas, Edwin Melencio
    Ballas, Leslie K.
    Berlin, Alejandro
    Hall, William A.
    Tran, Phuoc T.
    O'Daniel, Jennifer C.
    Hope, Thomas A.
    Rodgers, Joseph P.
    Feng, Felix Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [5] PROSTATE SBRT BOOST RADIOTHERAPY (PBS TRIAL): A RANDOMIZED PHASE II TRIAL OF SBRT VERSUS CONVENTIONALLY-FRACTIONATED RADIOTHERAPY BOOST FOLLOWING PELVIC RADIOTHERAPY IN HIGH-RISK PROSTATE CANCER
    Mesci, Aruz
    Isfahanian, Naghmeh
    Douvi, Georgia
    Gouran-Savadkoohi, Mohammad
    Dayes, Ian
    Lukka, Himanshu
    Quan, Kimmen
    Schnarr, Kara
    Goldberg, Mira
    Hallock, Abhirami
    Chow, Tom
    Diamond, Kevin
    Jakubovic, Raphael
    Thabane, Lahane
    Tsakiridis, Theodoros
    RADIOTHERAPY AND ONCOLOGY, 2021, 163 : S64 - S64
  • [6] Stereotactic body radiotherapy for high-risk prostate cancer (5 treatment days): Toxicity results of a phase II trial.
    Kishan, Amar Upadhyaya
    Fuller, Donald B.
    Steinberg, Michael L.
    Ramirez, Victoria
    Agazaryan, Nzhde
    Ruan, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [7] Acute Gastrointestinal and Genitourinary Toxicity Results from a Prospective Randomized Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3Dimensional Planning for Endometrial Cancer
    Nugent, K.
    Browne, D.
    Dunne, M.
    Osullivan, L.
    Shannon, A. M.
    Sharma, D.
    Bradshaw, S.
    McArdle, O.
    Salib, O.
    Lavan, N.
    Gillham, C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E702 - E702
  • [8] Anlotinib versus placebo as adjuvant therapy for completely resected high-grade soft tissue sarcomas: Interim results of a phase 2, double-blinded, randomized controlled trial
    Wang, Chun-Meng
    Hu, Xianglin
    Yang, Ling-ge
    Xu, Yu
    Huang, Wen-ding
    Zhang, Jian-rong
    Sun, Zheng-wang
    Chen, Mo
    Zheng, Bi-qiang
    Zhang, Sheng-jian
    Yu, Lin
    Fujiwara, Tomohiro
    Chen, Yong
    Sun, Yang-bai
    Houdek, Matthew T.
    Yan, Wangjun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] High-Dose-RATE Brachytherapy As Monotherapy for Low and Intermediate Risk Prostate Cancer: ACUTE Toxicity of a Randomized Phase II Trial
    Jolicoeur, M.
    Derashodian, T.
    Nguyen-Huynh, T. V.
    Hellmann, E. de Castro
    Mondat, M.
    Nachabe, M.
    Antebi, E.
    Wakil, G.
    Heliou, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E284 - E284
  • [10] Acute Toxicity Following Single-Dose Radiation Therapy in the Management of Intermediate Risk Prostate Cancer: Results from a Phase 2 Randomized Trial
    Greco, C.
    Pares, O.
    Pimentel, N.
    Louro, V.
    Arcangeli, S.
    Pinzi, V.
    Possanzini, M.
    Nunes, B.
    Morales, J.
    Stroom, J.
    Viera, S.
    Fuks, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E236 - E236
123